What is the half-life of Setmelanotide (Imcivree)?
Setmelanotide (Imcivree) has a reported half life of ~11 hours, given subcutaneous. That is why it is typically dosed once daily. A shorter half life means more frequent dosing to keep blood levels steady, a longer one lets you space doses further apart.
Quick facts
- Half-life: ~11 hours
- Route: Subcutaneous
- Typical schedule: Once daily
- Cycle length: Long-term in approved indications
References
- Setmelanotide for Obesity due to LEPR or POMC deficiency — Clément K et al., Lancet Diabetes Endocrinol, 2020
- Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alström syndrome: a phase 3 trial — Haqq AM et al., The Lancet Diabetes & Endocrinology, 2022
- Imcivree (setmelanotide) — Drugs@FDA approval record (ApplNo 213793) — FDA, Drugs@FDA
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Setmelanotide (Imcivree)
Last updated 2026-06-06.